Centessa Pharmaceuticals (CNTA) Shares Outstanding (Weighted Average) (2021 - 2026)

Centessa Pharmaceuticals (CNTA) has 6 years of Shares Outstanding (Weighted Average) data on file, last reported at $153.5 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 15.42% year-over-year to $153.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.5 million (up 15.42% YoY) and the FY2025 annual result came in at $135.7 million, up 18.56% from the prior year.
• Shares Outstanding (Weighted Average) improved to $153.5 million in Q1 2026 per CNTA's latest filing, from $135.7 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $153.5 million in Q1 2026 and bottomed at $90.5 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $99.9 million (2024), against an average of $110.0 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) soared 88.36%; it then advanced 2.97% in 2023.
• Tracing CNTA's Shares Outstanding (Weighted Average) over 5 years: stood at $93.4 million in 2022, then grew by 2.97% to $96.2 million in 2023, then climbed by 19.02% to $114.5 million in 2024, then advanced by 18.56% to $135.7 million in 2025, then grew by 13.14% to $153.5 million in 2026.
• Per Business Quant, the three latest CNTA Shares Outstanding (Weighted Average) figures stand at $153.5 million (Q1 2026), $135.7 million (Q4 2025), and $133.6 million (Q3 2025).

Peer Comparison